ATE502956T1 - Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften - Google Patents

Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften

Info

Publication number
ATE502956T1
ATE502956T1 AT06789808T AT06789808T ATE502956T1 AT E502956 T1 ATE502956 T1 AT E502956T1 AT 06789808 T AT06789808 T AT 06789808T AT 06789808 T AT06789808 T AT 06789808T AT E502956 T1 ATE502956 T1 AT E502956T1
Authority
AT
Austria
Prior art keywords
pdgf
angiogenic properties
modified vegf
improved
improved angiogenic
Prior art date
Application number
AT06789808T
Other languages
English (en)
Inventor
Kari Alitalo
Tuomas Tammela
Salla Keskitalo
Katri Pajusola
Markku Jeltsch
Seppo Yla-Herttuala
Terhi Karpanen
Ulf Eriksson
Marko Uutela
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Application granted granted Critical
Publication of ATE502956T1 publication Critical patent/ATE502956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Amplifiers (AREA)
AT06789808T 2005-08-15 2006-08-15 Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften ATE502956T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70822605P 2005-08-15 2005-08-15
PCT/US2006/032012 WO2007022287A2 (en) 2005-08-15 2006-08-15 Modified vegf and pdgf with improved angiogenic properties

Publications (1)

Publication Number Publication Date
ATE502956T1 true ATE502956T1 (de) 2011-04-15

Family

ID=37670985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06789808T ATE502956T1 (de) 2005-08-15 2006-08-15 Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften

Country Status (7)

Country Link
US (2) US8025886B2 (de)
EP (1) EP1919944B1 (de)
AT (1) ATE502956T1 (de)
AU (1) AU2006279462A1 (de)
DE (1) DE602006020881D1 (de)
ES (1) ES2363758T3 (de)
WO (1) WO2007022287A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
CN101392026B (zh) * 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽
MX2011010780A (es) * 2009-04-13 2011-10-28 Univ Northwestern Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso.
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
WO2012149515A2 (en) * 2011-04-29 2012-11-01 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US20160331807A1 (en) * 2014-01-21 2016-11-17 University Of Helsinki Therapeutic use of vegfr-3 ligands
CA3029332A1 (en) 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
CN107828819B (zh) * 2017-10-30 2020-11-03 武汉生物工程学院 一种利用ANP或IgANP基因构建重组腺病毒的方法及重组腺病毒和应用
JPWO2019098385A1 (ja) * 2017-11-20 2020-12-24 コニカミノルタ株式会社 薬剤評価方法
CN108774286A (zh) * 2018-06-28 2018-11-09 浙江众意生物科技有限公司 一种vegf-a单克隆抗体及试剂盒
CN114269792B (zh) * 2019-06-25 2025-08-08 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
CN119997965A (zh) * 2022-06-29 2025-05-13 天津大学 Pdgf-d前结构域及其变体和融合体

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580568A (en) 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5087244A (en) 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
EP0566245B1 (de) 1992-03-19 1999-10-06 Medtronic, Inc. Intraluminales Erweiterungsgerät
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US5280670A (en) 1992-11-02 1994-01-25 Tdw Delaware, Inc. Apparatus for repairing a transport pipe
US5336178A (en) 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6130071A (en) 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
ES2239338T5 (es) 1995-09-29 2013-05-31 Vegenics Pty Ltd Genes regulados y sus usos
US5653689A (en) 1995-09-30 1997-08-05 Abacus Design & Development, Inc. Infusion catheter
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5785965A (en) 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
FI100928B (fi) 1996-07-05 1998-03-13 Nokia Telecommunications Oy Tiedonsiirtomenetelmä
WO1998002543A1 (fr) 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
DE69732304T2 (de) 1996-11-01 2005-06-02 Ark Therapeutics Ltd. Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
US6428965B1 (en) 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
WO1999030157A2 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Neuropilins in methods for diagnosis and prognosis of cancer
CN1345247A (zh) 1997-12-24 2002-04-17 路德维格癌症研究所 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法
PT2016951E (pt) 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
US6238401B1 (en) 1998-07-31 2001-05-29 Zuli Holdings Ltd. Apparatus and method for selectively positioning a device and manipulating it
EP1123408A1 (de) * 1998-09-30 2001-08-16 Ludwig Institute For Cancer Research Von blutplättchen abstammender wachstumsfaktor c, dafür kodierende dns und dessen verwendungen
US20020164687A1 (en) 1998-09-30 2002-11-07 Ulf Eriksson Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20030211994A1 (en) 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
CA2345276C (en) 1998-10-09 2011-03-29 Ludwig Institute For Cancer Research Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO2000023565A2 (en) 1998-10-19 2000-04-27 Ludwig Institute For Cancer Research Novel neuropilin/growth factor binding and uses thereof
WO2000024412A2 (en) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
DE69931178T8 (de) 1998-11-02 2007-06-28 Ludwig Institute For Cancer Research Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
DK1129110T3 (da) 1998-11-10 2010-04-06 Ludwig Inst Cancer Res Blodpladeafledt vækstfaktor D, DNA kodende derfor og anvendelser deraf
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6965010B2 (en) 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
AU2001264565B2 (en) 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
SE0004929D0 (sv) 2000-12-29 2000-12-29 Apbiotech Ab A method for producing liquid chromatography matrices
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030064053A1 (en) 2001-08-31 2003-04-03 Shengjiang Liu Multivalent protein conjugate with multiple ligand-binding domains of receptors
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US6846323B2 (en) 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent
EP1635860A2 (de) 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US9307006B2 (en) 2012-04-11 2016-04-05 Salesforce.Com, Inc. System and method for synchronizing data objects in a cloud based social networking environment
JP6102573B2 (ja) 2013-06-28 2017-03-29 ブラザー工業株式会社 カートリッジ

Also Published As

Publication number Publication date
EP1919944A2 (de) 2008-05-14
US20120071406A1 (en) 2012-03-22
ES2363758T3 (es) 2011-08-16
DE602006020881D1 (de) 2011-05-05
EP1919944B1 (de) 2011-03-23
WO2007022287A3 (en) 2007-07-26
WO2007022287A2 (en) 2007-02-22
AU2006279462A1 (en) 2007-02-22
US20070142282A1 (en) 2007-06-21
US8025886B2 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
ATE502956T1 (de) Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
IL261585B (en) Human antigen-binding proteins that bind beta-klotho, fgf receptors and their complexes
PL2358756T5 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
CR20120105A (es) Proteínas terapéuticas de unión a dll4
UA112416C2 (uk) Антитіло до fap і способи його застосування
CY1116970T1 (el) Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης
EA201171494A1 (ru) Миметики белка smac
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EA201071421A1 (ru) Анти-flt3 антитела
MA34025B1 (fr) Polypeptides se liant au bêta-a
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
GT201300149A (es) Proteinas de union al tnf-a
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX2007013759A (es) Agentes de union de esclerostina.
MX2010010776A (es) Fusiones y conjugados de farmaco.
ATE519853T1 (de) Änderung des alkaloid-gehalts von tabak mittels modifizierung spezifischer p450-cytochromgene
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
EA201301108A1 (ru) Биспецифические связывающие молекулы, связывающиеся с vegf и ang2
EA201390611A1 (ru) Мультиспецифические антигенсвязывающие белки, направленные на hgf
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties